Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database

The changing landscape of biosimilars in rheumatology

(2016) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

(2015) Ashok Jha et al.   ADVANCES IN THERAPY

Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe

(2015) Fanni Rencz   WORLD JOURNAL OF GASTROENTEROLOGY

Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries

(2014) Ivo Abraham et al.   Future Oncology

Inequities in access to biologic and synthetic DMARDs across 46 European countries

(2013) Polina Putrik et al.   ANNALS OF THE RHEUMATIC DISEASES

Economic Evaluation of Levosimendan Versus Dobutamine for the Treatment of Acute Heart Failure in Italy

(2012) Carlo Lucioni et al.   ADVANCES IN THERAPY

Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?

(2012) Bassel El Zorkany et al.   CLINICAL RHEUMATOLOGY

Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

(2012) Matti Aapro et al.   Therapeutic Advances in Medical Oncology

Budget impact model of rituximab after failure of one or more TNFα inhibitor therapies in the treatment of rheumatoid arthritis

(2008) Robert Launois et al.   JOINT BONE SPINE